Giovanni Caforio
Net Worth

Last updated:

What is Giovanni Caforio net worth?

The estimated net worth of Dr. Giovanni Caforio is at least $136,412,390 as of 21 Mar 2022. He owns shares worth $28,110,870 as insider, has earned $21,331,520 from insider trading and has received compensation worth at least $86,970,000 in Bristol-Myers Squibb Company.

What is the salary of Giovanni Caforio?

Dr. Giovanni Caforio salary is $6,690,000 per year as Chairman & Chief Executive Officer in Bristol-Myers Squibb Company.

How old is Giovanni Caforio?

Dr. Giovanni Caforio is 60 years old, born in 1965.

What stocks does Giovanni Caforio currently own?

As insider, Dr. Giovanni Caforio owns shares in one company:

Company Title Shares Price per share Total value
Bristol-Myers Squibb Company (BMY) Chairman & Chief Executive Officer 581,524 $48.34 $28,110,870

What does Bristol-Myers Squibb Company do?

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

BMY logo
BMY
Bristol-Myers Squibb Company
$48.34

Giovanni Caforio insider trading

Bristol-Myers Squibb Company

Dr. Giovanni Caforio has made 15 insider trades between 2012-2022, according to the Form 4 filled with the SEC. Most recently he sold 25,000 units of BMY stock worth $1,788,000 on 21 Mar 2022.

The largest trade he's ever made was exercising 297,516 units of BMY stock on 10 Mar 2022. As of 21 Mar 2022 he still owns at least 581,524 units of BMY stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock, $0.10 par value 25,000 $71.52 $1,788,000
Option
Market Share Units 23,817 N/A N/A
Option
Common Stock, $0.10 par value 23,817 N/A N/A
Option
Performance Shares 297,516 N/A N/A
Option
Market Share Units 23,407 N/A N/A
Option
Common Stock, $0.10 par value 18,726 N/A N/A
Option
Market Share Units 24,793 N/A N/A
Option
Common Stock, $0.10 par value 24,793 N/A N/A
Option
Common Stock, $0.10 par value 148,758 N/A N/A
Option
Common Stock, $0.10 par value 23,407 N/A N/A
Sale
Common Stock, $0.10 par value 30,000 $67 $2,010,000
Sale
Common Stock, $0.10 par value 25,000 $60.64 $1,516,000
Sale
Common Stock, $0.10 par value 20,000 $68.58 $1,371,600
Sale
Common Stock, $0.10 par value 25,000 $62.2 $1,555,000
Option
Common Stock, $0.10 par value 200,709 N/A N/A
Option
Market Share Units 88,366 N/A N/A
Option
Common Stock, $0.10 par value 200,709 N/A N/A
Option
Market Share Units 88,366 N/A N/A
Option
Market Share Units 88,366 N/A N/A
Sale
Common Stock, $0.10 par value 39,840 $62.7 $2,497,968
Option
Market Share Units 83,142 N/A N/A
Option
Common Stock, $0.10 par value 211,796 N/A N/A
Option
Performance Shares 140,445 N/A N/A
Option
Common Stock, $0.10 par value 211,796 N/A N/A
Option
Market Share Units 83,142 N/A N/A
Option
Market Share Units 83,142 N/A N/A
Option
Common Stock, $0.10 par value 8,040 N/A N/A
Option
Market Share Units 8,040 N/A N/A
Option
Market Share Units 65,400 N/A N/A
Option
Common Stock, $0.10 par value 173,419 N/A N/A
Option
Market Share Units 65,400 N/A N/A
Option
Common Stock, $0.10 par value 173,419 N/A N/A
Option
Common Stock, $0.10 par value 8,040 N/A N/A
Option
Market Share Units 8,040 N/A N/A
Option
Market Share Units 52,378 N/A N/A
Option
Common Stock, $0.10 par value 219,211 N/A N/A
Option
Common Stock, $0.10 par value 8,040 N/A N/A
Option
Market Share Units 8,040 N/A N/A
Option
Market Share Units 35,815 N/A N/A
Option
Common Stock, $0.10 par value 87,604 N/A N/A
Option
Market Share Units 8,040 N/A N/A
Option
Common Stock, $0.10 par value 8,040 N/A N/A
Option
Common Stock, $0.10 par value 50,455 $25.07 $1,264,655
Option
Option (right to buy) 21,615 $27.01 $583,821
Sale
Common Stock, $0.10 par value 34,594 $71.31 $2,466,933
Option
Performance Shares 42,991 N/A N/A
Option
Common Stock, $0.10 par value 60,622 N/A N/A
Option
Market Share Units 17,631 N/A N/A
Option
Common Stock, $0.10 par value 2,889 N/A N/A
Option
Market Share Units 2,889 N/A N/A
Option
Common Stock, $0.10 par value 20,125 $22.89 $460,661
Option
Option (right to buy) 20,125 $22.89 $460,661
Sale
Common Stock, $0.10 par value 12,040 $63.58 $765,527
Option
Common Stock, $0.10 par value 10,579 N/A N/A
Option
Market Share Units 10,579 N/A N/A
Option
Market Share Units 2,889 N/A N/A
Option
Common Stock, $0.10 par value 2,889 N/A N/A
Option
Market Share Units 1,494 N/A N/A
Option
Common Stock, $0.10 par value 24,345 N/A N/A
Option
Restricted Stock Units 7,500 N/A N/A
Option
Common Stock, $0.10 par value 7,500 N/A N/A
Sale
Common Stock, $0.10 par value 26,691 $49.87 $1,331,160
Option
Common Stock, $0.10 par value 4,878 N/A N/A
Option
Market Share Units 4,878 N/A N/A
Option
Common Stock, $0.10 par value 2,889 N/A N/A
Option
Market Share Units 2,889 N/A N/A
Option
Common Stock, $0.10 par value 18,875 N/A N/A
Option
Market Share Units 2,691 N/A N/A
Option
Option (right to buy) 39,363 $17.51 $689,246
Option
Common Stock, $0.10 par value 39,363 $17.51 $689,246
Sale
Common Stock, $0.10 par value 41,563 $54.53 $2,266,264
Option
Restricted Stock Units 7,500 N/A N/A
Option
Common Stock, $0.10 par value 7,500 N/A N/A
Sale
Common Stock, $0.10 par value 10,538 $47.06 $495,918
Sale
Common Stock, $0.10 par value 26,647 $46.29 $1,233,490
Option
Option (right to buy) 21,333 $25.45 $542,925
Option
Common Stock, $0.10 par value 21,333 $25.45 $542,925
Option
Market Share Units 5,580 N/A N/A
Option
Common Stock, $0.10 par value 15,482 N/A N/A
Option
Performance Shares 9,902 N/A N/A
Option
Restricted Stock Units 1,851 N/A N/A
Option
Common Stock, $0.10 par value 1,851 N/A N/A
Sale
Common Stock, $0.10 par value 12,150 $37.08 $450,522
Option
Common Stock, $0.10 par value 22,500 $28.67 $645,075
Sale
Common Stock, $0.10 par value 20,350 $36.19 $736,467
Option
Option (right to buy) 22,500 $28.67 $645,075
Option
Common Stock, $0.10 par value 7,500 N/A N/A
Option
Restricted Stock Units 7,500 N/A N/A
Sale
Common Stock, $0.10 par value 25,900 $32.69 $846,671
Option
Option (right to buy) 30,458 $23.18 $705,925
Option
Common Stock, $0.10 par value 30,458 $23.18 $705,925
Option
Performance Shares 8,811 N/A N/A
Option
Common Stock, $0.10 par value 8,811 N/A N/A
Option
Common Stock, $0.10 par value 1,517 N/A N/A
Option
Restricted Stock Units 1,517 N/A N/A
Option
Restricted Stock Units 1,851 N/A N/A
Option
Common Stock, $0.10 par value 1,851 N/A N/A
Option
Common Stock, $0.10 par value 1,197 N/A N/A
Option
Market Share Units 1,197 N/A N/A
Option
Common Stock, $0.10 par value 1,493 N/A N/A
Option
Market Share Units 1,493 N/A N/A
Option
Common Stock, $0.10 par value 7,500 N/A N/A
Option
Restricted Stock Units 7,500 N/A N/A

Bristol-Myers Squibb Company key executives

Bristol-Myers Squibb Company executives and other stock owners filed with the SEC: